Role of nicotine dependence on the relationship between variants in the nicotinic receptor genes and risk of lung adenocarcinoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Tseng, Tung Sung ^a   Park, Jong Y ^b   Zabaleta, Jovanny ^c   Moody Thomas, Sarah ^a   Sothern, Melinda S ^a   Chen, Ted ^d   Evans, David E ^b   Lin, Hui Yi ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; NICOTINIC RECEPTOR;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHRNA3 GENE; CHRNA5 GENE; CHRNA6 GENE; CHRNB3 GENE; CHRNB4 GENE; CLPTM1L GENE; CONTROLLED STUDY; CYP1A1 GENE; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NICOTINE RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION PROGRAM; TERT GENE; TOBACCO DEPENDENCE; TP53 GENE; ADENOCARCINOMA; AGED; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; RISK FACTOR; SMOKING;

ADENOCARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NICOTINIC; RISK FACTORS; SMOKING; TOBACCO USE DISORDER;

EID: 84907225773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107268     Document Type: Article

References (81)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64: 9-29.
2. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005) International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299.
3. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
4. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355: 479-485.
5. Doria-Rose VP, Szabo E (2010) Screening and prevention of lung cancer; Kernstine KH, Reckamp KL, editors. New York: Demos Medical Publishing. 53-72 p.
6. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365: 395-409.
7. American Cancer Society (2013) Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
8. Weiss W (1997) Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest 111: 1414-1416.
9. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, et al. (1997) Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89: 1580-1586.
10. Gabrielson E (2006) Worldwide trends in lung cancer pathology. Respirology 11: 533-538.
11. Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, et al. (2002) Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Int J Cancer 99: 245-251.
12. Collins AC, Salminen O, Marks MJ, Whiteaker P, Grady SR (2009) The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol: 85-112.
13. Yokota J, Shiraishi K, Kohno T (2010) Genetic basis for susceptibility to lung cancer: Recent progress and future directions. Adv Cancer Res 109: 51-72.
14. Brennan P, Hainaut P, Boffetta P (2011) Genetics of lung-cancer susceptibility. Lancet Oncol 12: 399-408.
15. Hoft NR, Corley RP, McQueen MB, Schlaepfer IR, Huizinga D, et al. (2009) Genetic association of the CHRNA6 and CHRNB3 genes with tobacco dependence in a nationally representative sample. Neuropsychopharmacology 34: 698-706.
16. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, et al. (2010) Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 42: 448-453.
17. Zeiger JS, Haberstick BC, Schlaepfer I, Collins AC, Corley RP, et al. (2008) The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco. Hum Mol Genet 17: 724-734.
18. Hindorff LA, MacArthur J, Morales J, Junkins HA, Hall PN, et al. (2014) A Catalog of Published Genome-Wide Association Studies.
19. Xu CH, Wang Q, Qian Q, Zhan P, Yu LK (2013) CYP1A1 exon7 polymorphism is associated with lung cancer risk among the female population and among smokers: a meta-analysis. Tumour Biol.
20. Lee KM, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, et al. (2008) CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev 17: 1120-1126.
21. Ye XH, Bu ZB, Feng J, Peng L, Liao XB, et al. (2013) Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep.
22. Wang J, Spitz MR, Amos CI, Wilkinson AV, Wu X, et al. (2010) Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer 116: 3458-3462.
23. Vander Weele TJ, Asomaning K, Tchetgen Tchetgen EJ, Han Y, Spitz MR, et al. (2012) Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol 175: 1013-1020.
24. Siedlinski M, Tingley D, Lipman PJ, Cho MH, Litonjua AA, et al. (2013) Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. Hum Genet 132: 431-441.
25. Li MD (2006) The genetics of nicotine dependence. Curr Psychiatry Rep 8: 158-164.
26. Sullivan PF, Kendler KS (1999) The genetic epidemiology of smoking. Nicotine Tob Res 1 Suppl 2: S51-57; discussion S69-70.
27. Lerman C, Perkins KA, Gould T (2009) Nicotine dependence endophenotypes in chronic smokers. Bethesda, MD U.S. Department of Health and Human Services, National Institutes of Health.
28. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86: 1119-1127.
29. Buckley TC, Mozley SL, Holohan DR, Walsh K, Beckham JC, et al. (2005) A psychometric evaluation of the Fagerstrom Test for Nicotine Dependence in PTSD smokers. Addict Behav 30: 1029-1033.
30. Fidler JA, Shahab L, West R (2011) Strength of urges to smoke as a measure of severity of cigarette dependence: comparison with the Fagerstrom Test for Nicotine Dependence and its components. Addiction 106: 631-638.
31. DiFranza JR, Wellman RJ, Savageau JA, Beccia A, Ursprung WWSA, et al. (2013) What Aspect of Dependence Does the Fagerström Test for Nicotine Dependence Measure? ISRN Addiction, Article ID 906276, 8 pages 2013.
32. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, et al. (2009) A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85: 679-691.
33. Fagerstrom KO, Kunze M, Schoberberger R, Breslau N, Hughes JR, et al. (1996) Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokers. Tob Control 5: 52-56.
34. Gallus S, La Vecchia C (2004) A population-based estimate of tobacco dependence. Eur J Public Health 14: 93-94.
35. Diaz FJ, Jane M, Salto E, Pardell H, Salleras L, et al. (2005) A brief measure of high nicotine dependence for busy clinicians and large epidemiological surveys. Aust N Z J Psychiatry 39: 161-168.
36. Perez-Rios M, Santiago-Perez MI, Alonso B, Malvar A, Hervada X, et al. (2009) Fagerstrom test for nicotine dependence vs heavy smoking index in a general population survey. BMC Public Health 9: 493.
37. Baron RM, Kenny DA (1986) The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 51: 1173-1182.
38. MacKinnon DP, Lockwood CM, Brown CH, Wang W, Hoffman JM (2007) The intermediate endpoint effect in logistic and probit regression. Clinical Trials 4: 499-513.
39. Mackinnon DP, Dwyer JH (1993) Estimating Mediated Effects in Prevention Studies. Evaluation Review 17: 144-158.
40. Ditlevsen S, Christensen U, Lynch J, Damsgaard MT, Keiding N (2005) The mediation proportion: a structural approach for estimating the proportion of exposure effect on outcome explained by an intermediate variable. Epidemiology 16: 114-120.
41. Sobel ME (1982) Asymptotic confidence intervals for indirect effects in structural models. Sociological Methodology 13: 290-312.
42. Preacher KJ, Hayes AF (2004) SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput 36: 717-731.
43. Storey JD (2002) A direct approach to false discovery rates. Journal of the Royal Statistical Society: Series B 64: 479-498.
44. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
45. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
46. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40: 616-622.
47. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, et al. (2010) Metaanalysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet 42: 436-440.
48. Tobacco and Genetics Consortium. (2010) Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 42: 441-447.
49. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, et al. (2012) Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Am J Psychiatry 169: 735-742.
50. Hecht SS (2008) Progress and challenges in selected areas of tobacco carcinogenesis. Chem Res Toxicol 21: 160-171.
51. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, et al. (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111: 81-90.
52. Dasgupta P, Chellappan SP (2006) Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 5: 2324-2328.
53. Schuller HM (2009) Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 9: 195-205.
54. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, et al. (2008) Lung cancer susceptibility locus at 5p15.33. Nat Genet 40: 1404-1406.
55. Wang Y, Broderick P, Matakidou A, Eisen T, Houlston RS (2010) Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers. Carcinogenesis 31: 234-238.
56. Peres J (2011) Telomere research offers insight on stress-disease link. J Natl Cancer Inst 103: 848-850.
57. Desmaze C, Soria JC, Freulet-Marriere MA, Mathieu N, Sabatier L (2003) Telomere-driven genomic instability in cancer cells. Cancer Lett 194: 173-182.
58. Artandi SE, DePinho RA (2000) Mice without telomerase: what can they teach us about human cancer? Nat Med 6: 852-855.
59. Artandi SE, DePinho RA (2000) A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 10: 39-46.
60. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, et al. (2005) Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 173: 610-614.
61. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, et al. (2004) Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 22: 1807-1814.
62. Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE, et al. (1999) Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 54: 59-64.
63. Londono-Vallejo JA (2008) Telomere instability and cancer. Biochimie 90: 73-82.
64. Shay JW, Wright WE (2001) Telomeres and telomerase: implications for cancer and aging. Radiat Res 155: 188-193.
65. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, et al. (2003) Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95: 1211-1218.
66. Davison GM (2007) Telomeres and telomerase in leukaemia and lymphoma. Transfus Apher Sci 37: 43-47.
67. Granger MP, Wright WE, Shay JW (2002) Telomerase in cancer and aging. Critical Reviews in Oncology/Hematology 41: 29-40.
68. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK (2004) Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 164: 1523-1529.
69. Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J (2005) Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37: 977-990.
70. Widmann T, Kneer H, Konig J, Herrmann M, Pfreundschuh M (2008) Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol 36: 104-110.
71. Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, et al. (2008) Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol 9: 1048-1057.
72. Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, et al. (2011) Telomere length in myelodysplastic syndromes. Leuk Lymphoma 52: 1528-1536.
73. Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, et al. (2013) Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol 37: 434-439.
74. Ni Z, Tao K, Chen G, Chen Q, Tang J, et al. (2012) CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS One 7: e52598.
75. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y (2001) A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 280: 1148-1154.
76. Le Marchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, et al. (2008) Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res 68: 9137-9140.
77. Macqueen DA, Heckman BW, Blank MD, Janse Van Rensburg K, Park JY, et al. (2013) Variation in the alpha 5 nicotinic acetylcholine receptor subunit gene predicts cigarette smoking intensity as a function of nicotine content. Pharmacogenomics J.
78. Wang J, Shete S (2011) Power and type I error results for a bias-correction approach recently shown to provide accurate odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genet Epidemiol 35: 739-743.
79. Wang J, Shete S (2011) Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genet Epidemiol 35: 190-200.
80. Wang J, Spitz MR, Amos CI, Wu X, Wetter DW, et al. (2012) Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk. PLoS One 7: e47705.
81. Vanderweele TJ, Vansteelandt S (2010) Odds ratios for mediation analysis for a dichotomous outcome. Am J Epidemiol 172: 1339-1348.